📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

BofA more confident in Teva Pharma after management meetings

Published 11/13/2023, 01:29 PM
Updated 11/13/2023, 01:31 PM
© Reuters.  BofA more confident in Teva Pharma (TEVA) after management meetings

Investor sentiment on Teva Pharma's (NYSE:TEVA) story continues to improve, according to analysts at BofA, who reiterated a Buy rating and $13 per share price target on the stock on Monday.

The analysts explained to investors in a note that the firm hosted investor meetings with TEVA management, CEO Richard Francis, and CMO Eric Hughes last week.

"Overall, we felt investor sentiment on TEVA’s story continues to improve with a focus on continued execution and ‘24E validation of the ‘Pivot to Growth’ strategy (where EBITDA growth will be key)," the analysts wrote.

"We came away from the meetings more confident in TEVA’s ability to grow 2024+ EBITDA (BofA: $4.75bn or +5% vs. cons $4.63bn) on the strength of CNS brands, better margins (mix) and the trajectory of global generics."

Furthermore, BofA feels continued execution and resolution of small/manageable risk factors should expand TEVA’s investor appeal.

TEVA shares are up more than 1% at $8.80 per share at the time of writing on Monday. The stock is down around 4% in 2023.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.